Potential Drug Target for MEF2C in Muscle-Related Diseases (G4208)

Target Name: MEF2C

NCBI ID: G4208

MEF2C

Potential Drug Target for MEF2C in Muscle-Related Diseases

Myocyte-specific enhancer factor 2C (ISOform 1), also known as MEF2C, is a protein that plays a crucial role in the development and maintenance of muscle cells. It is a transcription factor that enhances the activity of several transcription factors, including Myosin light chain gene (MLG) and Pyruvate synthase gene (PSY), which are essential for muscle cell growth and function. MEF2C has been identified as a potential drug target and biomarker for several muscle-related diseases, including muscular dystrophy, myopathies, and neuromuscular disorders.

Structure and Function

MEF2C is a 21-kDa protein that consists of 208 amino acid residues. It has a characteristic Rossmann-fold structure that is commonly found in transcription factors. The protein has a nuclear localization and is predominantly expressed in muscle and neural tissues. MEF2C functions as a transcription factor by binding to specific DNA sequences and enhancing the activity of target genes.

MEF2C has been shown to play a critical role in the development and maintenance of muscle cells. It is required for the growth and survival of muscle cells, and it has been shown to regulate the expression of key genes involved in muscle development and function. MEF2C has been shown to promote the translation of its own genes and to inhibit the translation of genes involved in cell cycle progression and apoptosis.

MEF2C has also been shown to play a role in several muscle-related diseases. It is a potential drug target for muscular dystrophy, a genetic disorder that causes progressive muscle weakness and wasting. MEF2C has been shown to be downregulated in muscle cells from individuals with certain forms of muscular dystrophy, and it has been shown to enhance the activity of genes involved in muscle development and function in these individuals. It is also a potential biomarker for several other muscle-related diseases, including myopathies and neuromuscular disorders.

Drug Target Status

MEF2C is a potential drug target for several muscle-related diseases, including muscular dystrophy, myopathies, and neuromuscular disorders. Several studies have suggested that MEF2C may be a useful target for these diseases due to its role in the development and maintenance of muscle cells and its potential to enhance the activity of genes involved in muscle development and function.

MEF2C has been shown to be involved in several cellular processes that are involved in the development and maintenance of muscle cells. It has been shown to promote the translation of its own genes and to inhibit the translation of genes involved in cell cycle progression and apoptosis. It has also been shown to play a role in the regulation of muscle cell growth, as well as the maintenance of muscle cell survival.

MEF2C has been shown to be downregulated in muscle cells from individuals with certain forms of muscular dystrophy, which are characterized by progressive muscle weakness and wasting. It has been shown to enhance the activity of genes involved in muscle development and function in these individuals, suggesting that it may be a potential drug target for muscular dystrophy.

In addition to its role in the development and maintenance of muscle cells, MEF2C has also been shown to play a role in several other muscle-related diseases, including myopathies and neuromuscular disorders. It has been shown to be involved in the regulation of muscle cell growth and the maintenance of muscle cell survival, as well as the regulation of muscle protein synthesis and degradation.

MEF2C has also been shown to be a potential biomarker for several other muscle-related diseases, including myopathies and neuromuscular disorders. It has been shown to be downregulated in muscle cells from individuals with certain forms of these diseases,

Protein Name: Myocyte Enhancer Factor 2C

Functions: Transcription activator which binds specifically to the MEF2 element present in the regulatory regions of many muscle-specific genes. Controls cardiac morphogenesis and myogenesis, and is also involved in vascular development. Enhances transcriptional activation mediated by SOX18. Plays an essential role in hippocampal-dependent learning and memory by suppressing the number of excitatory synapses and thus regulating basal and evoked synaptic transmission. Crucial for normal neuronal development, distribution, and electrical activity in the neocortex. Necessary for proper development of megakaryocytes and platelets and for bone marrow B-lymphopoiesis. Required for B-cell survival and proliferation in response to BCR stimulation, efficient IgG1 antibody responses to T-cell-dependent antigens and for normal induction of germinal center B-cells. May also be involved in neurogenesis and in the development of cortical architecture (By similarity). Isoforms that lack the repressor domain are more active than isoform 1

The "MEF2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEF2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets